Navigation Links
Pharmacyclics Reports Second Quarter 2013 Results
Date:7/31/2013

Recent Developments & HighlightsTwo New England Journal of Medicine Publications
In June 2013, The New England Journal of Medicine (NEJM) published results from two Phase II studies of ibrutinib:  PCYC 1104-CA, a Phase II study evaluating  the safety and efficacy of ibrutinib monotherapy in patients with relapsed/refractory MCL; and PCYC 1102-CA, a Phase Ib/II study examining the safety and efficacy of ibrutinib monotherapy for the treatment of patients with relapsed/refractory CLL/ SLL, some of whom had deletion of part of chromosome 17 (del 17p). These data suggested ibrutinib may be effective and generally well-tolerated in patients with relapsed/refractory MCL and in patients with relapsed/refractory CLL/SLL. Both studies were originally presented at the annual meeting of the American Society of Hematology (ASH) in December 2012. Updated results from PCYC 1104-CA were presented at the European Hematology Association (EHA) Annual Meeting in June 2013.

Conferences and Presentations in June 2013
In June, Pharmacyclics and its collaborators presented 5 oral and 6 poster presentations on ibrutinib at three annual conferences: American Society of Clinical Oncology (ASCO), EHA, and the International Conference on Malignant Lymphoma (ICML).  These conferences showcased updated and expanded data in high risk CLL, relapsed or refractory MCL, and relapsed or refractory diffuse large B-cell lymphoma (DLBCL).  Also at these conferences ibrutinib data in two new areas were presented: Waldenstrom's Macroglobulinemia (WM) and frontline DLBCL in combination with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). All oral presentations made at these conferences have been filed in Form 8-K's with the SEC.

Selected Clinical Trials Initiated with Ibrutinib Over the Last 18 MonthsCLL/SLL

  • RESONATE™ (PCYC-1112) Phase III study of ibrutinib versus ofatumumab in patients wi
    '/>"/>

  • SOURCE Pharmacyclics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

    Related medicine technology :

    1. Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call
    2. Pharmacyclics Reports First Quarter 2013 Results
    3. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
    4. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
    5. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
    6. Pharmacyclics, Inc. Prices Public Offering of Common Stock
    7. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
    8. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
    9. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
    10. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
    11. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/30/2015)... , June 30, 2015  IGI Laboratories, Inc. ... based specialty generic pharmaceutical company, today announced it ... to the U.S. Food and Drug Administration (FDA) of ... submissions now pending at the FDA to twenty-seven. ... the Company, commented, "We believe our current pipeline of ...
    (Date:6/30/2015)... Dipexium Pharmaceuticals, Inc. (Nasdaq: DPRX ... the development and commercialization of Locilex® (pexiganan cream ... announced underwritten public offering of 1,480,000 shares of ... option in full to purchase an additional 222,000 ... proceeds to Dipexium are expected to be approximately ...
    (Date:6/30/2015)... 2015  Today, the National Mobility Equipment Dealers Association ... Mobility Awareness Month Local Heroes Contest on National TV. ... that received 1.3 million votes. The sponsors for the ... Mobility , and Valley Honda Dealers , with ... Vantage Mobility International (VMI) and ElDorado Mobility ...
    Breaking Medicine Technology:IGI Laboratories, Inc. Announces Fifth ANDA Submission Of 2015 2Dipexium Announces Closing of Public Offering of Common Stock 2Dipexium Announces Closing of Public Offering of Common Stock 3NMEDA Announces National Contest Winners 2NMEDA Announces National Contest Winners 3
    ... Aug. 2 Novalar Pharmaceuticals, Inc., a specialty pharmaceutical company focused ... again been selected by leading dental industry magazine Dentistry Today as one ... 24th annual competition were published in the July issue.   , ... OraVerse is the first ...
    ... , ST. LOUIS ,  Aug. 2 K-V Pharmaceutical ... received notification from the New York Stock Exchange ("NYSE") on ... quantitative continued listing standards.  The NYSE informed the Company that ... criteria for the average closing price of a NYSE security ...
    Cached Medicine Technology:OraVerse® Named as One of Dentistry Today's 'Top 100 Products' for Second Year 2OraVerse® Named as One of Dentistry Today's 'Top 100 Products' for Second Year 3K-V Pharmaceutical Company Notified by New York Stock Exchange of Non-Compliance With Continued Listing Standards 2K-V Pharmaceutical Company Notified by New York Stock Exchange of Non-Compliance With Continued Listing Standards 3K-V Pharmaceutical Company Notified by New York Stock Exchange of Non-Compliance With Continued Listing Standards 4K-V Pharmaceutical Company Notified by New York Stock Exchange of Non-Compliance With Continued Listing Standards 5K-V Pharmaceutical Company Notified by New York Stock Exchange of Non-Compliance With Continued Listing Standards 6K-V Pharmaceutical Company Notified by New York Stock Exchange of Non-Compliance With Continued Listing Standards 7K-V Pharmaceutical Company Notified by New York Stock Exchange of Non-Compliance With Continued Listing Standards 8K-V Pharmaceutical Company Notified by New York Stock Exchange of Non-Compliance With Continued Listing Standards 9
    (Date:6/30/2015)... , ... June 30, 2015 , ... ... UHMS approved 40-hour Introduction to Hyperbaric Medicine Course. Clinicians from WCA partnering hospitals ... hyperbaric medicine curriculum. , Wound care and hyperbaric medicine education and training ...
    (Date:6/30/2015)... IL (PRWEB) , ... June 30, 2015 , ... The ... educate women on fertility preservation and deciding the right age to pursue egg freezing. ... until after the age of 35 — a 150 percent increase since the 1970s. ...
    (Date:6/30/2015)... Sacramento, CA (PRWEB) , ... June 30, 2015 ... ... on YouTube titled, “University Post-Acute Rehab”. The video focuses on the rehab center’s ... Five-Star rating, indicating it provides the best quality of services available. Each patient ...
    (Date:6/30/2015)... ... June 30, 2015 , ... Lakeview Health, a ... doubled the size of its medical staff to further enhance its ability to ... physicians, nurse practitioners and physician assistants -- now totals 17, compared to 7 ...
    (Date:6/30/2015)... ... 2015 , ... Rocky Mountain Oils, a leading non-MLM supplier of premium ... new CEO, Mr. Darold Francis. The changes will help enhance the company’s focus on ... have come to know and respect for over eight years. , “I am thrilled ...
    Breaking Medicine News(10 mins):Health News:Wound Care Advantage Hosts Its First UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 2Health News:Wound Care Advantage Hosts Its First UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 3Health News:LIV Fertility Center Educating Women on the Critical Timing of Egg Freezing 2Health News:LIV Fertility Center Educating Women on the Critical Timing of Egg Freezing 3Health News:LIV Fertility Center Educating Women on the Critical Timing of Egg Freezing 4Health News:LIV Fertility Center Educating Women on the Critical Timing of Egg Freezing 5Health News:Patients of University Post-Acute Rehab Support Five-Star Rating in New Video 2Health News:Lakeview Health, a Nationally Recognized Drug Rehabilitation Center in Florida, Doubles Size of Medical Staff 2Health News:Rocky Mountain Oils Adds New CEO, Announces Relocation of Operations to Orem, Utah 2
    ... containing benadryl linked to slowed thinking, delirium in ... News) --Older people taking common over-the-counter drugs for ... increase their risk for cognitive impairment, including delirium, ... include Benadryl, Dramamine, Excedrin PM, Nytol, Sominex, Tylenol ...
    ... healthcare IT company by revenue , , HATBORO, Pa., June ... IFLG ), a leading technology provider of enterprise mobility solutions for ... been named to Healthcare Informatics , ... , , (Logo: http://www.newscom.com/cgi-bin/prnh/20071101/NETH165LOGO ...
    ... Programs Give Seniors Helpful Solutions , , HOUSTON, ... nation,s largest non-profit organization for seniors, with over 500,000 ... Support & Financial and Retirement Planning. , , ... of resources to SCB members, with the goal of ...
    ... ... based clinic - The London Clinic. The contract marks the world,s first live site of ... ... leading provider of clinical workflow and integration technology for the health care sector world-wide, has ...
    ... Best ... minded individual. , ... London, England (PRWEB) June 5, 2009 -- Best Pills Inc is proud to announce ... ,The site is unique in its offering of popularly prescribed "discreet" prescription drugs ...
    ... PROVO, Utah, June 4 Nu Skin Enterprises, Inc. (NYSE: ... has declared a quarterly dividend of $0.115 per share, which ... record on June 15, 2009. , , The ... has been demonstrating its tradition of innovation through its comprehensive ...
    Cached Medicine News:Health News:Some OTC Sleep, Cold Meds Could Harm Aging Brain 2Health News:Some OTC Sleep, Cold Meds Could Harm Aging Brain 3Health News:InfoLogix Named as One of the Top 50 Healthcare Information Technology Companies in the World 2Health News:InfoLogix Named as One of the Top 50 Healthcare Information Technology Companies in the World 3Health News:Senior Citizens Bureau Creates New Resourceful Divisions 2Health News:Orion Health Live at Harley Street Clinic 2Health News:Orion Health Live at Harley Street Clinic 3Health News:Bestpills Launchs its New Online Pharmacy 2
    ... The MicroAire® Hi Speed Pulse Lavage ... bone surfaces as well as cleansing ... Now a great system just got ... effective with the addition of ...
    ... Staple is a novel shape memory alloy bone ... of its Nitinol construction, the prongs of the ... upon application of a heating current. This results ... response of bone and cause adjustable compression across ...
    ... deformity of the ankle joint with ... fusion of the ankle joint, fractures ... where reconstruction is impossible, and fracture/dislocations ... severe arthritic changes and loss of ...
    The Buechel-pappas™ Total Ankle Replacement is a time-tested system which is the result of more than twenty years of development, clinical investigation, and use. The components have been avai...
    Medicine Products: